This presentation will discuss oligometastatic and oligoprogressive breast cancer and the rationale for different treatment paradigms and strategies. An overview of the evidence supporting these approaches will be presented with a particular focus on stereotactic ablative body radiotherapy (SABR) as a treatment strategy. The importance of integrating locally ablative therapies with systemic therapy will be discussed an overview of future directions will be presented.